There was a statistically significant increase in IFNγ+CD4+ T cells from participants vaccinated with ChAdOx1 nCoV-19 (P < 0.0001) and in IL-2+CD4+ T cells from recipients of GEMCOVAC-OM (P < 0.0001) from baseline to day 29. The gene discussed is CD4; the disease is ocular melanoma.